Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma.

Razzo BM, Ludwig N, Hong CS, Sharma P, Fabian KP, Fecek RJ, Storkus WJ, Whiteside TL.

Carcinogenesis. 2019 Jun 27. pii: bgz124. doi: 10.1093/carcin/bgz124. [Epub ahead of print]

PMID:
31245809
2.

Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma.

Ludwig S, Hong CS, Razzo BM, Fabian KPL, Chelvanambi M, Lang S, Storkus WJ, Whiteside TL.

Cancer Immunol Immunother. 2019 Jul;68(7):1133-1141. doi: 10.1007/s00262-019-02348-2. Epub 2019 May 28.

PMID:
31139925
3.

Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium.

Russell KL, Gorgulho CM, Allen A, Vakaki M, Wang Y, Facciabene A, Lee D, Roy P, Buchser WJ, Appleman LJ, Maranchie J, Storkus WJ, Lotze MT.

Cancer J. 2019 May/Jun;25(3):165-177. doi: 10.1097/PPO.0000000000000374.

PMID:
31135523
4.

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, Liu W, Storkus WJ, He Y, Liu Z, Bartlett DL.

J Immunother Cancer. 2019 Jan 9;7(1):6. doi: 10.1186/s40425-018-0495-7. Review.

5.

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C.

Cancer Immunol Immunother. 2019 Jan;68(1):109-120. doi: 10.1007/s00262-018-2259-0. Epub 2018 Oct 12.

PMID:
30315348
6.

Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.

Choi J, Beaino W, Fecek RJ, Fabian KPL, Laymon CM, Kurland BF, Storkus WJ, Anderson CJ.

J Nucl Med. 2018 Dec;59(12):1843-1849. doi: 10.2967/jnumed.118.209510. Epub 2018 Jun 29.

7.

Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.

Fabian KL, Storkus WJ.

Adv Exp Med Biol. 2017;1036:191-211. doi: 10.1007/978-3-319-67577-0_13. Review.

PMID:
29275473
8.

Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment.

Weinstein AM, Chen L, Brzana EA, Patil PR, Taylor JL, Fabian KL, Wallace CT, Jones SD, Watkins SC, Lu B, Stroncek DF, Denning TL, Fu YX, Cohen PA, Storkus WJ.

Oncoimmunology. 2017 Apr 28;6(6):e1322238. doi: 10.1080/2162402X.2017.1322238. eCollection 2017.

9.

Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity.

Liu Z, Hao X, Zhang Y, Zhang J, Carey CD, Falo LD Jr, Storkus WJ, You Z.

Oncoimmunology. 2017 Apr 24;6(6):e1315487. doi: 10.1080/2162402X.2017.1315487. eCollection 2017.

10.

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, Storkus WJ, Bartlett DL.

Front Immunol. 2017 May 15;8:555. doi: 10.3389/fimmu.2017.00555. eCollection 2017. Review.

11.

Tumor-Derived α-Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death.

Vujanovic L, Stahl EC, Pardee AD, Geller DA, Tsung A, Watkins SC, Gibson GA, Storkus WJ, Butterfield LH.

Cancer Immunol Res. 2017 Jun;5(6):493-502. doi: 10.1158/2326-6066.CIR-16-0216. Epub 2017 May 3.

12.

Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.

Fabian KP, Chi-Sabins N, Taylor JL, Fecek R, Weinstein A, Storkus WJ.

Oncoimmunology. 2017 Feb 10;6(3):e1290035. doi: 10.1080/2162402X.2017.1290035. eCollection 2017.

13.

Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.

Tarhini AA, Tawbi H, Storkus WJ.

Melanoma Manag. 2016 Dec;3(4):251-254. doi: 10.2217/mmt-2016-0016. Epub 2016 Nov 29. No abstract available.

14.

Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.

Fecek RJ, Storkus WJ.

Immunotherapy. 2016 Oct;8(10):1205-18. doi: 10.2217/imt-2016-0071. Review.

15.

Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO.

Weinstein AM, Storkus WJ.

Front Immunol. 2016 Aug 9;7:301. doi: 10.3389/fimmu.2016.00301. eCollection 2016. Review.

16.

Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses.

Raïch-Regué D, Fabian KP, Watson AR, Fecek RJ, Storkus WJ, Thomson AW.

Oncoimmunology. 2016 Mar 23;5(6):e1146841. doi: 10.1080/2162402X.2016.1146841. eCollection 2016 Jun.

17.

Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells.

Ghosh T, Barik S, Bhuniya A, Dhar J, Dasgupta S, Ghosh S, Sarkar M, Guha I, Sarkar K, Chakrabarti P, Saha B, Storkus WJ, Baral R, Bose A.

Int J Cancer. 2016 Nov 1;139(9):2068-81. doi: 10.1002/ijc.30265. Epub 2016 Jul 22.

18.

miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.

Gigante M, Pontrelli P, Herr W, Gigante M, D'Avenia M, Zaza G, Cavalcanti E, Accetturo M, Lucarelli G, Carrieri G, Battaglia M, Storkus WJ, Gesualdo L, Ranieri E.

J Transl Med. 2016 Apr 11;14:84. doi: 10.1186/s12967-016-0841-9.

19.

Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.

Weinstein AM, Storkus WJ.

Adv Cancer Res. 2015;128:197-233. doi: 10.1016/bs.acr.2015.04.003. Epub 2015 May 5. Review.

20.

Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity.

Zhang Y, Chen G, Liu Z, Tian S, Zhang J, Carey CD, Murphy KM, Storkus WJ, Falo LD Jr, You Z.

J Immunol. 2015 Jun 15;194(12):5937-47. doi: 10.4049/jimmunol.1500089. Epub 2015 May 13.

21.

Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.

Zhang Y, Tian S, Liu Z, Zhang J, Zhang M, Bosenberg MW, Kedl RM, Waldmann TA, Storkus WJ, Falo LD Jr, You Z.

Oncoimmunology. 2014 Dec 15;3(10):e959321. eCollection 2014 Nov.

22.

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

Wesa AK, Mandic M, Taylor JL, Moschos S, Kirkwood JM, Kwok WW, Finke JH, Storkus WJ.

Front Oncol. 2014 Sep 29;4:266. doi: 10.3389/fonc.2014.00266. eCollection 2014.

23.

Monitoring antigen-specific T cell responses using real-time PCR.

Lowe DB, Taylor JL, Storkus WJ.

Methods Mol Biol. 2014;1186:65-74. doi: 10.1007/978-1-4939-1158-5_5.

24.

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.

Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ.

Oncoimmunology. 2014 Jan 1;3(1):e27589. Epub 2014 Feb 27.

25.

Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8+ T-cell responses.

Vujanovic L, Shi J, Kirkwood JM, Storkus WJ, Butterfield LH.

Oncoimmunology. 2014 Nov 14;3(8):e954501. eCollection 2014.

26.

Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity.

Chen L, Fabian KL, Taylor JL, Storkus WJ.

Front Immunol. 2013 Nov 29;4:388. doi: 10.3389/fimmu.2013.00388. Review.

27.

DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.

Chi Sabins N, Taylor JL, Fabian KP, Appleman LJ, Maranchie JK, Stolz DB, Storkus WJ.

Mol Ther. 2013 Oct;21(10):1958-68. doi: 10.1038/mt.2013.133. Epub 2013 Jul 30.

28.

Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells.

Chen L, Taylor JL, Sabins NC, Lowe DB, Qu Y, You Z, Storkus WJ.

Cancer Gene Ther. 2013 Aug;20(8):469-77. doi: 10.1038/cgt.2013.42. Epub 2013 Jul 12.

29.

Tumor-derived vascular pericytes anergize Th cells.

Bose A, Barik S, Banerjee S, Ghosh T, Mallick A, Bhattacharyya Majumdar S, Goswami KK, Bhuniya A, Banerjee S, Baral R, Storkus WJ, Dasgupta PS, Majumdar S.

J Immunol. 2013 Jul 15;191(2):971-81. doi: 10.4049/jimmunol.1300280. Epub 2013 Jun 19.

30.

Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12.

Janelsins BM, Sumpter TL, Tkacheva OA, Rojas-Canales DM, Erdos G, Mathers AR, Shufesky WJ, Storkus WJ, Falo LD Jr, Morelli AE, Larregina AT.

Blood. 2013 Apr 11;121(15):2923-33. doi: 10.1182/blood-2012-07-446054. Epub 2013 Jan 30.

31.

Shock block for improved immunotherapy.

Rao A, Lowe DB, Storkus WJ.

Oncoimmunology. 2012 Nov 1;1(8):1427-1429.

32.

Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, Rayman PA, Rini BI, Gendler SJ, Finke JH.

Immunol Invest. 2012;41(6-7):680-710. doi: 10.3109/08820139.2012.703745. Review.

33.

Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells.

Rao A, Taylor JL, Chi-Sabins N, Kawabe M, Gooding WE, Storkus WJ.

Cancer Res. 2012 Jul 1;72(13):3196-206. doi: 10.1158/0008-5472.CAN-12-0538. Epub 2012 May 2. Erratum in: Cancer Res. 2012 Oct 15;72(20):5431.

34.

Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

Bose A, Lowe DB, Rao A, Storkus WJ.

Melanoma Res. 2012 Jun;22(3):236-43. doi: 10.1097/CMR.0b013e3283538293.

35.

Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.

Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ.

J Immunol. 2012 Feb 15;188(4):1782-8. doi: 10.4049/jimmunol.1101644. Epub 2012 Jan 13.

36.

Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.

Qu Y, Chen L, Lowe DB, Storkus WJ, Taylor JL.

Mol Ther. 2012 Mar;20(3):644-51. doi: 10.1038/mt.2011.283. Epub 2012 Jan 3.

37.

Chronic inflammation and immunologic-based constraints in malignant disease.

Lowe DB, Storkus WJ.

Immunotherapy. 2011 Oct;3(10):1265-74. doi: 10.2217/imt.11.113. Review.

38.

Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32.

Qu Y, Taylor JL, Bose A, Storkus WJ.

Cancer Gene Ther. 2011 Sep;18(9):663-73. doi: 10.1038/cgt.2011.37. Epub 2011 Jul 15.

39.

Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.

Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, Watkins SC, Butterfield LH, Kalinski P, Kirkwood JM, Storkus WJ.

Mol Ther. 2011 Apr;19(4):805-14. doi: 10.1038/mt.2010.295. Epub 2010 Dec 28.

40.

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ.

Int J Cancer. 2011 Nov 1;129(9):2158-70. doi: 10.1002/ijc.25863. Epub 2011 May 25.

41.

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ.

Cancer Res. 2010 Nov 15;70(22):9041-52. doi: 10.1158/0008-5472.CAN-10-1369. Epub 2010 Nov 2.

42.

Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment.

Qu Y, Chen L, Pardee AD, Taylor JL, Wesa AK, Storkus WJ.

J Immunol. 2010 Sep 1;185(5):2895-902. doi: 10.4049/jimmunol.1001294. Epub 2010 Jul 30.

43.

JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.

Cavalcanti E, Gigante M, Mancini V, Battaglia M, Ditonno P, Capobianco C, Cincione RI, Selvaggi FP, Herr W, Storkus WJ, Gesualdo L, Ranieri E.

J Biomed Biotechnol. 2010;2010:935764. doi: 10.1155/2010/935764. Epub 2010 Mar 22.

44.

Integrating costimulatory agonists to optimize immune-based cancer therapies.

Pardee AD, Wesa AK, Storkus WJ.

Immunotherapy. 2009 Mar;1(2):249-64. doi: 10.2217/1750743X.1.2.249. Review.

45.

Update on vaccine development for renal cell cancer.

Chi N, Maranchie JK, Appleman LJ, Storkus WJ.

Open Access J Urol. 2010 Aug 4;2:125-41. Review.

46.

DC expressing transgene Foxp3 are regulatory APC.

Lipscomb MW, Taylor JL, Goldbach CJ, Watkins SC, Wesa AK, Storkus WJ.

Eur J Immunol. 2010 Feb;40(2):480-93. doi: 10.1002/eji.200939667.

47.

Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.

Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ.

J Immunol. 2009 Dec 1;183(11):7250-8. doi: 10.4049/jimmunol.0901477. Epub 2009 Nov 13.

48.

IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.

Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ.

J Immunother. 2009 Oct;32(8):793-802. doi: 10.1097/CJI.0b013e3181acec1e.

49.

Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes.

Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL.

J Immunol. 2009 Sep 15;183(6):3720-30. doi: 10.4049/jimmunol.0900970. Epub 2009 Aug 19.

50.

Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

Kawabe M, Mandic M, Taylor JL, Vasquez CA, Wesa AK, Neckers LM, Storkus WJ.

Cancer Res. 2009 Sep 1;69(17):6995-7003. doi: 10.1158/0008-5472.CAN-08-4511. Epub 2009 Aug 18.

Supplemental Content

Loading ...
Support Center